Completed OBSERVATIONAL NCT03790631

The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring (OPTIMAL TDM)

Sponsor: University Hospital, Geneva

Conditions Amoxicillin Beta-lactam Antibiotics Cefepime Ceftazidime Efficacy Flucloxacillin Imipenem Meropenem Piperacillin Therapeutic Drug Monitoring Toxicity

Interventions The study is observational.

Updated 8 times since 2019 Last updated: May 14, 2025 Started: Jan 14, 2019 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03790631, this observational or N/A phase trial focuses on Amoxicillin and Beta-lactam Antibiotics and remains completed. Sponsored by University Hospital, Geneva, it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Jun 2025 — Present [monthly]

Completed

Status: Recruiting → Completed
Sep 2024 — Jun 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2023 — Jul 2024 [monthly]

Recruiting
Jun 2021 — Jun 2023 [monthly]

Recruiting

▶ Show 3 earlier versions

Jan 2021 — Jun 2021 [monthly]

Recruiting
Mar 2019 — Jan 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Jan 2019 — Mar 2019 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Geneva
University of Geneva, Switzerland

Data source: University of Geneva, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland